Verici Dx (Verici Dx) Change In Inventory : $0.00 Mil (TTM As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Change In Inventory?

Verici Dx's change in inventory for the quarter that ended in Jun. 2023 was $0.00 Mil. It means Verici Dx's inventory stayed the same from Dec. 2022 to Jun. 2023 .

Verici Dx's change in inventory for the fiscal year that ended in Dec. 2022 was $0.00 Mil. It means Verici Dx's inventory stayed the same from Dec. 2021 to Dec. 2022 .

Verici Dx's Total Inventories for the quarter that ended in Jun. 2023 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Verici Dx's Days Inventory for the quarter that ended in Jun. 2023 was 0.00.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Verici Dx's Inventory-to-Revenue for the quarter that ended in Jun. 2023 was 0.00.

Verici Dx Change In Inventory Historical Data

The historical data trend for Verici Dx's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Change In Inventory Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Change In Inventory

Verici Dx Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23
Change In Inventory	-	-	-	-	-

Verici Dx Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

Verici Dx (OTCPK:VRCDF) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Verici Dx's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0.003	*	365 / 2
	=	0.00

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Verici Dx's Inventory Turnover for the quarter that ended in Jun. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0.003	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Verici Dx's Inventory to Revenue for the quarter that ended in Jun. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0.019
	=	0.00

Verici Dx Change In Inventory Related Terms

Thank you for viewing the detailed overview of Verici Dx's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx (Verici Dx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

VRCI:UK

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (Verici Dx) Headlines

No Headlines